Study on the Safety and Effectiveness of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Inclusion Criteria

• Diagnosed with recurrent glioblastoma, a type of brain cancer, after standard treatments like radiation and chemotherapy.
• No more than two recurrences of the cancer.
• At least 18 years old.
• Able to perform daily activities with a performance status of 60% or higher.
• Have good bone marrow and organ function based on specific blood test results.
• Women and men must agree to use effective birth control during the study and for four months after.
• Must have recovered from any side effects of previous cancer treatments to a mild level.
• Stable or decreasing doses of steroids and anti-seizure medications before starting the study drugs.
• Able to understand and sign a consent form to participate in the study.

Exclusion Criteria

• Have not responded to previous anti-VEGF-A therapy or had significant side effects from it.
• Have had recent cancer treatments, including certain drugs or therapies, within a specified time before starting the study.
• Use of certain medications like aspirin or anticoagulants shortly before starting the study drugs.
• History of certain bleeding or gastrointestinal conditions.
• History of serious cardiovascular diseases in the past five years.
• Have had significant vascular diseases recently.
• For Arm 2: Previous treatment with specific immune-oncology therapies.
• For Arm 2: Recent use of systemic non-steroidal immunosuppressive agents.
• Have had organ or cell transplants.
• For Arm 2: Recent live vaccinations.
• Have other cancers that could interfere with the study.
• Allergic reactions to similar drugs as CTX-009 or CTX-471.
• Uncontrolled seizure disorder or other serious illnesses.
• Pregnant or breastfeeding women.
• HIV-positive patients not on effective treatment.
• Active hepatitis B or C infections unless controlled or cured.